Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2006-12-29
2010-10-26
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S141100, C424S145100
Reexamination Certificate
active
07820155
ABSTRACT:
The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.
REFERENCES:
patent: 6086874 (2000-07-01), Yoshida et al.
patent: 6969517 (2005-11-01), Gillies et al.
patent: 2006/0257407 (2006-11-01), Chen et al.
patent: WO-0107081 (2001-02-01), None
patent: WO-02072605 (2002-09-01), None
patent: WO-2004039826 (2004-05-01), None
patent: WO-2004045507 (2004-06-01), None
patent: WO-2004071404 (2004-08-01), None
patent: WO-2005005638 (2005-01-01), None
Beers and Berkow (1999). The Merck Manual of Diagnosis and Therapy , 17thedition, pp. 986-995.
Chuntharapai et al (1997) Method in Enzymology, vol. 288, pp. 15-27.
BD Pharmingen, (2006) “Technical Data Sheet: Purified Rat Anti-Human IL-6 Monoclonal Antibody (ELISA Capture),” Catalog No. 554543, 0.5 mg.
Boulanger, M.J. et al., (2003) “Hexameric structure and assembly of the interleukin-6/IL-6 α-Receptor/gp130 complex ”Science300:2101-2104.
Brakenhoff, J. et al., (1990) “Structure-Function analysis of human IL-6: epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants,”J. Immunol.145(2):561-568.
Davies, J. et al., (1996) “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,”Immunotechnology2(3):169-179.
eBioscience, (2007) “Product Information: Functional Grade Purified anti-human interleukin-6 (IL6),” Catalog No. 16-7069.
Fischer, M. et al., (1997) “A bioactive designer cytokine for human hematopoietic progenitor cell expansion,”Nat. Biotechnol.15:142-145.
Georgii-Hemming, P. et al., (1996) “Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines,”Blood88:2250-2258.
Gillies, S. et al., (1989) “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes,”J. Immunol. Methods125(1-2):191-202.
Holt, L. J. et al., (2003) “Domain antibodies: proteins for therapy,”Trends Biotechnol.21(11):484-490.
International Preliminary Report on Patentability for international application No. PCT/EP2006/012236, issued by the International Bureau of WIPO on Jul. 1, 2008, 14 pages.
International Search Report for application No. PCT/EP2006/012236, mailed from the European Patent Office as International Searching Authority on May 21, 2007, 6 pages.
Köhler, G. et al., (1975) “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature256:495-497.
Lehrnbecher et al., (1999) “Assessment of Measuring Circulating Levels of Interleukin-6, Interleukin-8, C-Reactive Protein, Soluble Fcγ Receptor Type III, and Mannose-Binding Protein in Febrile Children with Cancer and Neutropenia,”Clin. Infect. Dis.29:414-9.
Little, M. et al., (2000) Of mice and men: hybridoma and recombinant antibodies:Immunol. Today21(8):364-370.
Peters, M. et al., (1998) “In vivo and in vitro activities of the gp130-stimulating designer cytokine hyper-IL-6,”J. Immunol.161:3575-3581.
Scheller, J. et al., (2004) “Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition,”J. Immunol. Methods291:93-100.
van de Winkel, J. G. J. et al., (1993) “Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications,”Immunol. Today14(5):215-221.
van Zaanen, H.C.T. et al., (1996) “Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop,”J. Clin. Invest.98(6):1441-1448.
Wyant, T. et al., (1999) “Potent immunoregulatory effects ofSalmonella typhiflagella on antigenic stimulation of human peripheral blood mononuclear cells,”Infect. Immun.67(3): 1338-1346.
Zaki, M. et al., (2004) “CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice,”Int. J. Cancer111:592-595.
Zou, J.P. et al., (1999) “Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) That Alters Monocyte Cytokine Profile and Surface Markers,”J. Immunol.162: 4882-4892.
Goodwin & Procter LLP
Merck Patent GmbH
Mertz Prema
LandOfFree
Methods of treating cancer comprising administering an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating cancer comprising administering an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cancer comprising administering an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4241865